Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Federal Trade Commission
AstraZeneca
Covington
Citi
Accenture

Generated: September 17, 2019

DrugPatentWatch Database Preview

Patent: 8,435,540

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,435,540
Title:Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in VIVO
Abstract: The present invention concerns methods and compositions for PEGylated complexes of defined stoichiometry and structure. Preferably, the PEGylated complex is formed using dock-and-lock technology, by attaching a therapeutic agent to a DDD sequence and a PEG moiety to an AD sequence, allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two therapeutic agents and one PEG moiety. Alternatively, the therapeutic agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one therapeutic agent. In more preferred embodiments, the therapeutic agent may comprise any peptide or protein of physiologic or therapeutic activity, preferably a cytokine, more preferably interferon-.alpha.2b. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases.
Inventor(s): Chang; Chien-Hsing (Downingtown, PA), Goldenberg; David M. (Mendham, NJ), McBride; William J. (Boonton, NJ), Rossi; Edmund A. (Woodland Park, NJ)
Assignee: IBC Pharmaceuticals, Inc. (Morris Plains, NJ)
Application Number:13/412,816
Patent Claims:see list of patent claims

Details for Patent 8,435,540

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering PEGINTRON peginterferon alfa-2b VIAL 103949 001 2001-01-19 ➤ Sign Up IBC Pharmaceuticals, Inc. (Morris Plains, NJ) 2025-04-06 RX Orphan search
Schering PEGINTRON peginterferon alfa-2b VIAL 103949 002 2001-01-19 ➤ Sign Up IBC Pharmaceuticals, Inc. (Morris Plains, NJ) 2025-04-06 RX Orphan search
Schering PEGINTRON peginterferon alfa-2b VIAL 103949 003 2001-01-19 ➤ Sign Up IBC Pharmaceuticals, Inc. (Morris Plains, NJ) 2025-04-06 RX Orphan search
Schering PEGINTRON peginterferon alfa-2b VIAL 103949 004 2001-01-19 ➤ Sign Up IBC Pharmaceuticals, Inc. (Morris Plains, NJ) 2025-04-06 RX Orphan search
Schering PEGINTRON peginterferon alfa-2b SYRINGE 103949 005 2001-01-19 ➤ Sign Up IBC Pharmaceuticals, Inc. (Morris Plains, NJ) 2025-04-06 RX Orphan search
Schering PEGINTRON peginterferon alfa-2b SYRINGE 103949 006 2001-01-19 ➤ Sign Up IBC Pharmaceuticals, Inc. (Morris Plains, NJ) 2025-04-06 RX Orphan search
Schering PEGINTRON peginterferon alfa-2b SYRINGE 103949 007 2001-01-19 ➤ Sign Up IBC Pharmaceuticals, Inc. (Morris Plains, NJ) 2025-04-06 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
QuintilesIMS
Cantor Fitzgerald
Johnson and Johnson
McKinsey
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.